NASDAQ: RENB - Renovaro Biosciences Inc.

Yield per half year: -34.8%
Dividend yield: 0%
Sector: Healthcare

Share chart Renovaro Biosciences Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Renovaro Biosciences Inc.

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV.

more details
It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-02-02
ISIN US29350E1047
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.renovarobio.com
Цена ао 0.335
Change price per day: -3.3% (0.333)
Change price per week: +1.9% (0.316)
Change price per month: -10.56% (0.36)
Change price per 3 month: -60.2% (0.809)
Change price per half year: -34.8% (0.4939)
Change price per year: -66.8% (0.97)
Change price per 3 year: -95.81% (7.69)
Change price per 5 year: -91.23% (3.67)
Change price per year to date: -71.25% (1.12)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.16 9
P/E 0 0
EV/EBITDA -1.97 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -72.84 0
ROE, % -90.37 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0476 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 42.56 6
Yield Ebitda, % 609.97 10
Yield EPS, % 241.32 10
Total: 7.4
More

Institutions Volume Share, %
Vanguard Group Inc 390107 1.01
Morgan Stanley 362978 0.94
Geode Capital Management, LLC 362409 0.93
Blackrock Inc. 304656 0.79
Millennium Management LLC 126314 0.33
Susquehanna International Group, LLP 119459 0.31
State Street Corporation 97687 0.25
Northern Trust Corporation 88101 0.23
683 Capital Management LLC 73706 0.19
Qube Research & Technologies Ltd 67978 0.18



Head Job title Payment Year of birth
Dr. Francois Binette M.Sc., Ph.D. COO and Executive VP for Research & Development 504.38k 1964 (61 year)
Dr. Serhat Gümrükcü Co-Founder & Inventor N/A
Mr. Greg Duczynski Ph.D. Senior Vice President for Clinical Operations N/A
Hon. Mark R. Dybul M.D. CEO, Director & Member of HBV Scientific Advisory Board 764.58k 1963 (62 years)
Mr. Simon Tarsh Interim Chief Financial Officer N/A 1961 (64 years)

Address: United States, Los Angeles. CA, 2080 Century Park East - open in Google maps, open in Yandex maps
Website: https://www.renovarobio.com